06:01 EST Novo Nordisk (NVO) shares drop 27% premarket after releasing Cagrisema data
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk says patients on Cagrisema lost 22.7% of weight in trial
- Novo Nordisk: Cagrisema weight loss showed superiority over semaglutide
- Novo Nordisk to further explore weight loss potential of Cagrisema
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Lennox to replace Catalent in S&P 500 at open on 12/23